Frontiers in Endocrinology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 21, 2025
This
mini
review
explores
the
increasing
prevalence
of
obesity
in
type
1
diabetes
(T1D)
and
challenges
patients
face
achieving
optimal
glycemic
control
with
current
treatments.
It
discusses
evidence
supporting
use
glucagon-like
peptide-1
receptor
agonists
(GLP-1RA)
as
potential
adjunctive
therapy
T1D
to
reduce
weight
improve
insulin
resistance.
Potential
benefits
need
be
weighed
against
risk
hypoglycemia
lack
long-term
data.
JAMA Psychiatry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Importance
Preclinical,
observational,
and
pharmacoepidemiology
evidence
indicates
that
glucagon-like
peptide
1
receptor
agonists
(GLP-1RAs)
may
reduce
alcohol
intake.
Randomized
trials
are
needed
to
determine
the
clinical
significance
of
these
findings.
Objective
To
evaluate
effects
once-weekly
subcutaneous
semaglutide
on
consumption
craving
in
adults
with
use
disorder
(AUD).
Design,
Setting,
Participants
This
was
a
phase
2,
double-blind,
randomized,
parallel-arm
trial
involving
9
weeks
outpatient
treatment.
Enrollment
occurred
at
an
academic
medical
center
US
from
September
2022
February
2024.
Of
504
potential
participants
assessed,
48
non–treatment-seeking
AUD
were
randomized.
Intervention
received
(0.25
mg/week
for
4
weeks,
0.5
1.0
mg
week)
or
placebo
weekly
clinic
visits.
Main
Outcomes
Measures
The
primary
outcome
laboratory
self-administration,
measured
pretreatment
posttreatment
(0.5
mg/week).
Secondary
exploratory
outcomes,
including
prospective
changes
craving,
assessed
Results
Forty-eight
(34
[71%]
female;
mean
[SD]
age,
39.9
[10.6]
years)
Low-dose
reduced
amount
consumed
during
self-administration
task,
medium
large
effect
sizes
grams
(β,
−0.48;
95%
CI,
−0.85
−0.11;
P
=
.01)
peak
breath
concentration
−0.46;
−0.87
−0.06;
.03).
Semaglutide
treatment
did
not
affect
average
drinks
per
calendar
day
number
drinking
days,
but
significantly
−0.41;
−0.73
−0.09;
.04)
−0.39;
.01),
also
predicting
greater
reductions
heavy
over
time
relative
0.84;
0.71
0.99;
.04).
A
significant
treatment-by-time
interaction
indicated
predicted
cigarettes
subsample
individuals
current
cigarette
−0.10;
−0.16
−0.03;
.005).
Conclusions
Relevance
These
findings
provide
initial
low-dose
can
some
justifying
larger
GLP-1RAs
disorder.
Trial
Registration
ClinicalTrials.gov
Identifier:
NCT05520775
Archives of Gynecology and Obstetrics,
Journal Year:
2025,
Volume and Issue:
311(5), P. 1241 - 1247
Published: Jan. 7, 2025
Abstract
Purpose
Metabolic
disease,
including
obesity
and
type
2
diabetes,
are
amongst
the
most
significant
health
issues
facing
women
of
reproductive
age.
To
date,
no
antenatal
weight
management
tools
have
reduced
risk
adverse
outcomes
for
with
their
offspring,
resulting
in
a
shift
focus
to
pre-conception
period.
Although
not
yet
recognised
international
guidelines,
glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs)
being
increasingly
used
prior
conception.
Methods
A
literature
search
PubMed,
Medline,
Embase
databases
identified
relevant
articles
describing
use
GLP-1
RAs
during
pregnancy.
Papers
were
selected
based
on
relevance
originality,
clinical
trials,
large
observational
studies
meta-analyses
preferentially
included.
Results
This
narrative
review
summarises
mechanism
action
effects
observed
non-pregnant
adults.
It
synthesises
available
data
from
human
animal
regarding
safety
efficacy
pregnancy,
consequences
inadvertent
drug
exposure
early
In
considering
need
balance
risks
metabolic
disease
posed
by
exposure,
it
highlights
areas
where
further
research
is
needed
guide
decision-making.
Conclusion
may
role
facilitating
loss
improving
However,
there
currently
insufficient
evidence
demonstrate
that
this
class
drugs
pregnancy
improves
outcomes.
Endocrinology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 15, 2025
Abstract
Obesity
is
now
considered
a
chronic
relapsing
progressive
disease,
associated
with
increased
all-cause
mortality
that
scales
bodyweight,
affecting
more
than
1
billion
people
worldwide.
Excess
body
fat
strongly
excess
energy
intake,
and
most
successful
anti-obesity
medications
(AOMs)
counter
this
positive
balance
through
the
suppression
of
eating
to
drive
weight
loss.
Historically,
AOMs
have
been
characterised
by
modest
loss
side
effects
which
are
compliance-limiting,
in
some
cases
life-threatening.
However,
field
obesity
pharmacotherapy
has
entered
new
era
based
on
analogues
gut
hormone
neuropeptide
glucagon-like
peptide-1
(GLP-1).
The
latest
versions
these
drugs
elicit
unprecedented
levels
clinical
trials,
starting
be
substantiated
real-world
usage.
Notably,
reduce
primarily
reducing
via
activation
GLP-1
receptor
multiple
sites
action
CNS,
although
relevant
action,
neural
circuits
recruited
remain
contentious.
Here
we
provide
targeted
synthesis
recent
developments
neurobiology,
highlighting
studies
advanced
our
understanding
how
signalling
modulates
eating,
identify
open
questions
future
challenges
believe
still
need
addressed
aid
prevention
and/or
treatment
obesity.
